3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
3
Prostatic Neoplasms
2
Neoplasms
2
Smoking
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ototoxicity
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hyperlipoproteinemia Type II
1
Hematologic Neoplasms
1
Hemangioma, Cavernous, Central Nervous System
1
Hearing Loss
1
Head and Neck Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Colitis, Ulcerative
1
Cardiotoxicity
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
14
Nivolumab
10
Ipilimumab
10
Axitinib
6
cabozantinib
5
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Atorvastatin
×
1 year
×
Clear all
NCT05796973
2025-06-27
MOVES
Tampere University Hospital
Phase 3
Recruiting
240 enrolled